Results 171 to 180 of about 4,863 (192)
Some of the next articles are maybe not open access.
Siltuximab: A new option for the management of Castleman's disease
Drugs of Today, 2015Castleman's disease is a rare lymphoproliferative disorder the underlying mechanism of which remains unclear. However, interleukin-6 (IL-6) may play a role in the pathogenesis of the disease. Blockade of the IL-6 pathway has been explored in multiple preclinical and clinical studies with promising results for the treatment of different types of cancer ...
openaire +2 more sources
Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease
BioDrugs, 2015Siltuximab (Sylvant™), an interleukin (IL)-6 chimeric immunoglobulin Gк monoclonal antibody, is a currently the only agent approved to treat human idiopathic (herpesvirus-8 negative) multicentric Castleman disease (iMCD), which is a rare lymphoproliferative disorder.
openaire +2 more sources
Myelopathy Because of CAR-T–Related Neurotoxicity Treated With Siltuximab
Neurology Clinical Practice, 2021Yasmin, Aghajan +6 more
openaire +2 more sources
Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.
Prescrire international, 2016Multicentric Castleman's disease is a rare lymphoproliferative disorder characterised by disseminated lymphadenopathy. Symptoms and outcomes differ widely from one patient to another. The median survival time is about 2.5 years. There is no consensus on treatment.
openaire +1 more source